A Multicenter, International, Phase 3, Double-blind, Placebo-controlled, Randomized Study To Evaluate The Efficacy, Safety, And Tolerability Of Daily Oral Dosing Of Tafamidis Meglumine (Pf-06291826) 20 Mg Or 80 Mg In Comparison To Placebo In Subjects Diagnosed With Transthyretin Cardiomyopathy (ttr-cm)

Trial Profile

A Multicenter, International, Phase 3, Double-blind, Placebo-controlled, Randomized Study To Evaluate The Efficacy, Safety, And Tolerability Of Daily Oral Dosing Of Tafamidis Meglumine (Pf-06291826) 20 Mg Or 80 Mg In Comparison To Placebo In Subjects Diagnosed With Transthyretin Cardiomyopathy (ttr-cm)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Tafamidis meglumine (Primary)
  • Indications Cardiomyopathies
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTR-ACT
  • Sponsors FoldRx Pharmaceuticals; Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Apr 2017 Status changed from suspended to active, no longer recruiting.
    • 06 Apr 2017 Status changed from active, no longer recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top